MedTrace Logo

A Study of IGN002 for Refractory NHL

NCT02847949 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-03-11

No results posted yet for this study

Summary

This is a Phase 1 multi-center, open-label study that allows subjects who derived clinical benefit after completing IGN002 treatment in the Spectrum sponsored IGN002-101 study to continue treatment with IGN002. Subjects who completed the IGN002-101 study, tolerated IGN002 treatment, and did not experience progressive disease (PD) are eligible to participate in this study.

Conditions

  • NHL

Interventions

BIOLOGICAL

IGN002

IGN002 is a monoclonal antibody fusion protein

Sponsors & Collaborators

  • The Leukemia and Lymphoma Society

    collaborator OTHER

  • Spectrum Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • John Timmerman · University of California, Los Angeles

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-31
Primary Completion
2025-07-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02847949 on ClinicalTrials.gov